Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

  1. Voss, M.H.
  2. Gordon, M.S.
  3. Mita, M.
  4. Rini, B.
  5. Makker, V.
  6. Macarulla, T.
  7. Smith, D.C.
  8. Cervantes, A.
  9. Puzanov, I.
  10. Pili, R.
  11. Wang, D.
  12. Jalal, S.
  13. Pant, S.
  14. Patel, M.R.
  15. Neuwirth, R.
  16. Enke, A.
  17. Shou, Y.
  18. Sedarati, F.
  19. Faller, D.V.
  20. Burris, H.A.
Aldizkaria:
British Journal of Cancer

ISSN: 1532-1827,  0007-0920

Argitalpen urtea: 2020

Alea: 123

Zenbakia: 11

Orrialdeak: 1590-1598

Mota: Artikulua

DOI: 10.1038/S41416-020-01041-X GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus